Post written by: BioTech Health X
You May Also Like
Novavax (NVAX): A Game-Changer in Biotechnology and a Smart Investment Choice
- BioTech Health X
- November 29, 2024
- 3 minute read
Table of Contents Hide A Vision for a Healthier Future Strategic Partnerships: Expanding Market Presence Globally A Resilient…
Sanara MedTech (SMTI) Achieves Record $21.7M Revenue in Q3 2024
- BioTech Health X
- January 2, 2025
- 4 minute read
Table of Contents Hide Third Quarter 2024 Financial Performance: A Record-Breaking StreakOperational and Earnings InsightsStrategic Initiatives and Business…
Thermo Fisher (TMO) Is Everywhere—And That’s Exactly Why It’s Winning
- BioTech Health X
- July 23, 2025
- 6 minute read
Table of Contents Hide Strong Financial Performance and Growth MomentumA Resilient Business Model Supported by Secular TailwindsOperational Excellence…
Oramed (ORMP) Eyes Comeback with Oral GLP-1 and NASH Pipeline Expansion
- BioTech Health X
- May 30, 2025
- 5 minute read
Table of Contents Hide Overcoming Setbacks: From Disappointment to Strategic ReassessmentAdvancing the Pipeline: Expanding Beyond Insulin to Address…
BenchSci Expands Advisory Board with New Pharma R&D Leaders
- BioTech Health X
- April 21, 2022
- 2 minute read
BenchSci has welcomed three new members to its advisory board from the pharmacology sector. Steve Hitchcock of Takeda…
CEL-SCI Advances in Cancer Treatment with FDA Approval for Confirmatory Multikine Study
- BioTech Health X
- May 8, 2024
- 2 minute read
In a landmark decision, the U.S. Food and Drug Administration (FDA) has green-lighted CEL-SCI Corporation (NYSE American: CVM)…